COVID-19 negative (n=17) | COVID-19 positive (n=12) | P value | Without MetS (n=7) | MetS (n=5) | P value | |

Age in years, median (IQR) | 59.0 (47.30–65.8) | 51.5 (40.3–61.0) | 0.97 | 46.00 (40.00–61.00) | 54.00 (41.50–70.00) | 0.876 |

BMI in kg/m)^{2}, median (IQR | 27.2 (25.4–29.9) | 28.68 (24.28–31.83) | 0.507 | 27.04 (23.51–30.47) | 31.86 (25.77–38.98) | 0.149 |

Waist–hip ratio, median (IQR) | 0.96 (0.89–1.03) | 0.95 (0.89–1.01) | 0.632 | 0.95 (0.76–0.99) | 0.95 (0.90–1.03) | 0.755 |

MetS, N (%) | 7 (41.0) | 5 (41.7) | 0.979 | – | – | – |

Leptin (pg/mL), median (IQR) | 20 034.4 (3229.7–30 026.6) | 20 870.3 (7593.0–37 178.9) | 0.235 | 20 581.3 (6878.1–29 815.6) | 35 643.8 (13 675.0–63 581.3) | 0.108 |

Adiponectin (ng/mL), median (IQR) | 4467.5 (2834.0–9645.5) | 5663.9 (3679.6–8498.3) | 0.677 | 7671.7 (5148.2–9766.0) | 3687.4 (2392.9–6233.2) | 0.106 |

Leptin–adiponectin ratio, median (IQR) | 2.6 (0.9–6.3) | 3.8 (1.9–6.5) | 0.631 | 1.9 (1.2–3.7) | 6.6 (5.2–12.9) | 0.003 |

IL-6 (pg/mL), median (IQR) | <MDD | 42.08 (22.44–94.81) | – | 70.01 (30.8–119.5) | 30.6 (9.3–51.7) | 0.028 |

Measurements of IL-6, leptin and adiponectin in a subgroup of patients. Several relevant clinical parameters, such as BMI, waist–hip ratio and presence of MetS are shown. Median (IQR Q1–Q3) used in variables with non-normal distribution. Statistically significant p-values are bold.

BMI, body mass index; IL-6, interleukin 6 ; MDD, minimum detectable dose; MetS, metabolic syndrome; N, numbers.